A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Public ClinicalTrials.gov record NCT00289627. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Study identification
- NCT ID
- NCT00289627
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 155 participants
Conditions and interventions
Conditions
Interventions
- ipilimumab (MDX-010, BMS-734016) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2006
- Primary completion
- Jun 30, 2007
- Completion
- Jun 30, 2007
- Last update posted
- Sep 27, 2016
2006 – 2007
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Park Ridge | Illinois | — | — |
| Not listed | Goshen | Indiana | — | — |
| Not listed | Hazard | Kentucky | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Charlottesvillle | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00289627, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2016 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00289627 live on ClinicalTrials.gov.